Zymeworks INC 8-K filings

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma, Inc. for approximately $929 million, adding the COPD treatment YUPELRI to its portfolio and financing the deal through a combination of cash and a $350 million non-recourse note.

Zymeworks Inc. announced a new $125 million share repurchase program, replacing its previous authorization, and expects its cash resources to fund operations beyond 2028.

Zymeworks Inc. announced the appointment of Kristin Stafford, a seasoned finance executive with extensive life sciences experience, as its new Executive Vice President and Chief Financial Officer, effective April 1, 2026.

Zymeworks has secured $250 million in non-recourse royalty-backed financing from Royalty Pharma, leveraging future Ziihera royalties to bolster its balance sheet and fund strategic initiatives.

Zymeworks reported a 39% revenue increase and reduced net loss in 2025, bolstered by a $250M royalty-backed note and anticipated Ziihera regulatory approvals.

Zymeworks announced a strategic pivot towards asset aggregation, significant leadership changes, and positive clinical data for Ziihera, alongside preliminary cash runway guidance beyond 2028.

Zymeworks Inc. announced the results of its 2025 annual meeting of stockholders, where all director nominees were elected, executive compensation was approved, and KPMG LLP was ratified as auditor.

Zymeworks Inc. announced a new strategic initiative to optimize cash flows from licensed products, authorized a $125 million share repurchase program, and appointed Scott Platshon as Acting Chief Investment Officer.

Zymeworks announced positive topline results from its Phase 3 HERIZON-GEA-01 trial, indicating Ziihera's potential as a new standard of care for first-line HER2-positive gastroesophageal adenocarcinoma.

Zymeworks announced its third quarter 2025 financial results, highlighting encouraging clinical data, a significant milestone payment, and an extended cash runway.

Zymeworks Inc. announced the voluntary discontinuation of clinical development for its T cell engager ZW171, citing an unfavorable benefit-risk profile.

Zymeworks Inc. announced the appointment of two new directors, including one who will participate in a $4.99 million private placement, alongside a board resignation.

Zymeworks Inc. announced a significant financial turnaround in Q2 2025 with a net income of $2.3 million, driven by key partnership milestones and regulatory approvals for zanidatamab, extending its cash runway into the second half of 2027.

Zymeworks Inc. announced the amendment and full exercise of pre-funded warrants by EcoR1 Capital, leading to the issuance of over 5 million new common shares and an increase in EcoR1's beneficial ownership.

Zymeworks Inc. announced that China's National Medical Products Administration (NMPA) has granted conditional approval for zanidatamab, its dual HER2-targeted bispecific antibody, for the treatment of previously treated, unresectable or metastatic HER2-positive biliary tract cancer, marking a significant regulatory and financial milestone.

Zymeworks announced its Q1 2025 financial results, highlighting progress in its R&D pipeline, including upcoming presentations and regulatory milestones, and reported a cash runway into 2H-2027.

Zymeworks announced its Q4 and full year 2024 financial results, highlighting the advancement of its clinical pipeline and the FDA approval of Ziihera for biliary tract cancer.

Zymeworks Inc. appoints Oleg Nodelman, Founder and Portfolio Manager of EcoR1 Capital, LLC, to its board of directors, effective February 17, 2025.

Zymeworks reports a strong cash position of $324 million and anticipates funding operations into the second half of 2027.

Zymeworks Inc. held its 2024 annual meeting, electing directors, approving executive compensation, ratifying the auditor, and adjusting non-employee director compensation.

Zymeworks and Jazz Pharmaceuticals announce FDA accelerated approval of Ziihera for previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.

Zymeworks reported its Q3 2024 financial results, highlighted by a first patient dosed in a Phase 1 trial for ZW171 and the completion of an initial $30 million share repurchase program.

Zymeworks Inc. reports the resignation of Hollings C. Renton from the board of directors and subsequent appointments to the compensation committee.

Zymeworks Inc. has officially appointed Leone Patterson as Executive Vice President, Chief Business Officer, and Chief Financial Officer, effective September 1, 2024, while Kenneth Galbraith steps down from his interim CFO role.

Zymeworks Inc. has established an at-the-market sales agreement with TD Securities (USA) LLC to potentially sell up to $150 million of its common stock.

Zymeworks has authorized a share repurchase program of up to $60 million, signaling confidence in its future and extending its cash runway into the second half of 2027.

Zymeworks reported $395.9 million in cash resources and provided updates on its clinical programs, including regulatory milestones for zanidatamab and the advancement of new drug candidates.

Zymeworks Inc. has appointed Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024.

Zymeworks Inc. announced that the Chinese regulatory authority has accepted the biologics license application for zanidatamab, triggering an $8 million milestone payment.

Zymeworks Inc. has filed prospectus supplements related to the potential issuance of common stock, including shares issuable upon exchange of exchangeable shares and shares offered through an at-the-market (ATM) program.